Compare · BCLI vs GILD
BCLI vs GILD
Side-by-side comparison of Brainstorm Cell Therapeutics Inc. (BCLI) and Gilead Sciences Inc. (GILD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BCLI and GILD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $190.38B, about 1709.4x BCLI ($111.4M).
- Over the past year, BCLI is up 0.0% and GILD is up 32.8% - GILD leads by 32.8 points.
- GILD has hit the wire 4 times in the past 4 weeks while BCLI has been quiet.
- GILD has more recent analyst coverage (25 ratings vs 0 for BCLI).
- Company
- Brainstorm Cell Therapeutics Inc.
- Gilead Sciences Inc.
- Price
- $1.18-1.67%
- $156.44-0.62%
- Market cap
- $111.4M
- $190.38B
- 1M return
- +0.00%
- +3.63%
- 1Y return
- +0.00%
- +32.77%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- News (4w)
- 0
- 4
- Recent ratings
- 0
- 25
Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and in Phase II for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other central nervous system disorders. The company has a partnership with Catalent for the manufacture of NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest BCLI
- BrainStorm Executive Leadership to Participate in DUPHAT 2026; Executive Chairman Peter J. Pitts Invited to Deliver Two Keynote Addresses and Moderate Panel Sessions
- SEC Form 10-Q filed by Brainstorm Cell Therapeutics Inc.
- Brainstorm Cell Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update
- Brainstorm Cell Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Director Frenkel Jacob A was granted 100,000 shares, increasing direct ownership by 41% to 343,777 units (SEC Form 4)
- SEC Form 4 filed by Executive Chairman Pitts Peter Joe
- BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman
- SEC Form 3 filed by new insider Pitts Peter Joe
- SEC Form EFFECT filed by Brainstorm Cell Therapeutics Inc.
Latest GILD
- SEC Form 144 filed by Gilead Sciences Inc.
- Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
- Chairman & CEO O'Day Daniel Patrick sold $2,218,508 worth of shares (15,000 units at $147.90) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 566,683 units (SEC Form 4)
- SVP, Controllership Burkhart Erin converted options into 2,223 shares and covered exercise/tax liability with 768 shares (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $435,870 worth of shares (3,000 units at $145.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 164,096 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna sold $432,646 worth of shares (3,000 units at $144.22) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 116,684 units (SEC Form 4)
- A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
- Chief Financial Officer Dickinson Andrew D converted options into 2,797 shares and covered exercise/tax liability with 1,347 shares, increasing direct ownership by 0.88% to 167,096 units (SEC Form 4)
- Chief Medical Officer Berger Dietmar converted options into 533 shares and covered exercise/tax liability with 263 shares, increasing direct ownership by 1% to 19,522 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna converted options into 2,797 shares and covered exercise/tax liability with 1,347 shares, increasing direct ownership by 1% to 119,684 units (SEC Form 4)